Welcome to the Sun Pharma Stock Liveblog, your go-to platform for real-time updates and analysis on a top-performing stock.

After a US Court blocked the launch of Leqselvi, a drug used to treat severe alopecia areata, shares of Sun Pharma plunged ...

Welcome to the Sun Pharma Stock Liveblog, your ultimate source for real-time updates and analysis of one of the most ...

Thirty out of the 41 analysts tracking the company have a 'buy' rating on the stock, seven suggest a 'hold' and four have a ...

According to Citi, the delay in the launch of Sun Pharma's alopecia areata drug, Leqselvi, could impact its near-term ...

In the worst-case scenario, an unfavourable judgment would prevent Sun Pharma from launching Leqselvi until the patent expires, delaying its market entry.

Earlier on Monday, Sun Pharma reported a 28 per cent increase in its consolidated net profit to Rs 3,040 crore in Q2 FY2025.

Most brokerages retained ratings and target prices for Sun Pharmaceutical Industries after its second quarter earnings beat ...

This decision delays Sun Pharma's planned US launch of the product, which could be deferred for several months if the company ...

Sun Pharmaceuticals Ltd., the country's largest drugmaker, on Monday (October 28), reported a net profit of ₹3,040 crore, ...

Led by growth in its domestic business, the specialty generic pharma company is expected to post good July-September quarter.